EP1189636A2 - Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme - Google Patents

Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme

Info

Publication number
EP1189636A2
EP1189636A2 EP00961512A EP00961512A EP1189636A2 EP 1189636 A2 EP1189636 A2 EP 1189636A2 EP 00961512 A EP00961512 A EP 00961512A EP 00961512 A EP00961512 A EP 00961512A EP 1189636 A2 EP1189636 A2 EP 1189636A2
Authority
EP
European Patent Office
Prior art keywords
salt solution
aqueous salt
redox potential
electroactivated aqueous
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00961512A
Other languages
German (de)
English (en)
Inventor
Robert G. Khatchatrian
Ashot P. Khatchatrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1189636A2 publication Critical patent/EP1189636A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to a method of treating human immunodeficiency diseases with electroactivated aqueous salt solutions followed by reconstitution of a healthy microflora.
  • Acquired immune deficiency syndrome is a disease of the human immune system.
  • the immunodeficient state is reflected in an inability of the immune system to respond to various antigens.
  • the immunodeficient state may allow for the growth of tumors, due to a defect in the normal a ⁇ titumor activity of the immune system.
  • the immunodeficient state may also lead to allergic or autoimmune problems.
  • the development of an immunodeficient state is often caused by metabolic disorders. These metabolic disorders may result from diabetes, obesity, artherosclerosis, uremia and attrition.
  • Irritable colon syndrome is a common aspect of many diseases and is often connected with problems in the immune system.
  • Many diseases that appear unrelated, such as AIDS, chronic renal failure, bacterial endocarditis, and bronchial asthma are related by a unified feature: irritable colon syndrome, a common disruption of the balance of microflora in the intestine and growth of pathogenic bacteria.
  • the disruption of the balance of microflora, followed by disruption of the immune system determines the onset and course of many diseases.
  • novel methods of treatment of immunodeficient states can be achieved through the development of new methods of purifying an organism from pathogenic accumulations, normalizing metabolism, and restoring the healthy intestinal microflora. Such methods would make it possible for a person to control the illness by a natural means.
  • hexapeptide drug is administered through hypodermic injections. (Patent of Russian Federation No. 2062096). This drug has shown good results in the treatment of immunodeficient patients with chronic and active persistent hepatitis B, brucellosis and chronic bronchitis.
  • patients suffering from AIDS or AIDS-related syndromes are treated by the injection of a pharmaceutical composition containing zidovudin (31-azid-31-deoxythymidine) and inosyplex (paracyd-benzoic acid), possibly in combination with inosinum.
  • zidovudin 31-azid-31-deoxythymidine
  • inosyplex paracyd-benzoic acid
  • Another method of treating immunodeficient patients uses a solution of water mixed with either sodium
  • a method of treating irritable colon syndrome that may also be used to treat immunodeficiencies involves purification of the intestine with enemas. This is followed by the implantation of microflora in the intestine with the help of colonoscopy. Lactobacteria is implanted in the ascending section of the intestine, Bifidobacteria is implanted in the transversal section and colibacteria is implanted in the descending section. (Patent of Russian Federation No. 2092167). Unfortunately, aside from the cleansing enemas, this method does not contemplate removing pathogenic agents from the intestine and thus is not as effective as it might be.
  • Another method of treating autoimmune diseases, as well as AIDS consists of inhibiting, removing or neutralizing a variety of growth factors, antigens or receptors.
  • This treatment comprises either administering the active molecules directly to the patient's blood or removing the patient's blood, treating it, and returning it to the patient. (U.S. Patent No. 5,888,511).
  • magnesium gluconate may be administered alone or in combination with antioxidants or anti- inflammatory agents.
  • Additional methods use pharmacologically accepted salts, such as
  • the present invention relates to a method of treating humans suffering from a disease.
  • the method comprises rectall ⁇ administering to said human an electroactivated aqueous salt solution with negative redox potential. This is followed by implantation of bacteria in the intestine to restore a healthy microflora.
  • the method may additionally comprise administering an electroactivated aqueous salt solution with negative redox potential orally or by injection.
  • the method of the present invention may also comprise rinsing the oral cavity, nasopharynx and vaginal cavity with an electroactivated aqueous salt solution with positive redox potential.
  • the method of the present invention is a preventative and treatment for immunodeficiencies.
  • the aim of the present invention is to provide a more effective method to prevent and treat immune diseases through intensive decontamination and the restoration of the microflora found in the healthy individual (healthy microflora).
  • the method of the present invention comprises a course of treatment.
  • the first step comprises the administration of electroactivated aqueous salt solutions to the patient.
  • Preferably the volume of electroactivated aqueous salt solution administered does not exceed the daily requirements for electrolytes and water.
  • Aqueous solutions of salts with negative or positive redox potential are activated by any method known in the art. Preferably they are activated on a membranous electrolyzer. Any membranous electrolyzer known in the art may be used. For example, a membranous electrolyzer of the Espero type may be used.
  • the measured values are preferably -300 to -1200 mV and pH 8.0 to 12.0. More preferably, the measured values are -500 to -900 mV and pH 9.0 to 1 1.0.
  • the measured values are preferably +500 to + 1200 mV and pH 0.05 to 5.0.
  • the measured values are + 900 to + 1200 and pH 1.0 to 2.0.
  • the salt may be any salt known in the art.
  • the salt is preferably either AgN0 3 , in a density of no more than 14 grams/liter or a mixture of the salts NaCI, KCI, CaCI 2 and MgCI 2 , in any ratio and at a density of no more than 15 grams/liter. More preferably the salt is either AgN0 3 in a density of no more than 7 grams/liter or the salts NaCI, KCI, CaCI 2 and MgCI 2 in the same ratio as they are found in plasma (80:2:2:1) and at a density of no more than 10 grams/liter.
  • the electroactivated aqueous solution of salts with negative redox potential is administered to the patient through three separate routes. First, it is administered to the patient by way of intravenous injection of preferably no more than 400 ml per day. More preferably no more than 200 ml/day is administered.
  • it is administered orally, in an amount of no more than 600 ml per day, for 40 days. More preferably it is administered orally before a meal in an amount of no more than 300 ml per day for 1 to 20 days. Finally, it is administered by way of cleansing enemas, preferably in an amount of 3 liters, twice a day. More preferably it is administered by enema in an amount of 0.5 to 1.5 liters, once per day.
  • the electroactivated aqueous solution of salts with positive redox potential is also administered to the patient in a number of ways. First, it is administered as an aerosol with a particle size of no more than 10 microns.
  • the aerosol is administered as an aerosol with a particle size of no more than 3.5 microns.
  • the aerosol is inhaled through the nose or mouth.
  • 1 to 10 ml are inhaled four times per day. More preferably, 1 to 3 ml are inhaled twice a day, once in the morning and once in the evening.
  • vaginal cavity in female patients it is administered by way of rinsing vaginal cavity with an amount of 10 to 800 ml four times per day. More preferably it is administered by this route twice a day in an amount of 200 to 400 ml.
  • the oral cavity and nasopharynx are administered by way of rinsing the oral cavity and nasopharynx with an amount of 10 to 800 ml four times per day. More preferably it is administered by this route twice a day in an amount of 200 to 400 ml.
  • the healthy microflora is restored.
  • bacteria are implanted in the intestine with the aid of a colo ⁇ oscopy. Any bacteria known in the art may be implanted following any procedure known in the art.
  • lactobacteria, bifidobacteria and colibacteria are implanted in the following manner.
  • a culture of lactobacteria is implanted in the ascending section of the intestine through a biopsy canal.
  • a culture of bifidobacteria is implanted in the transverse section of colon.
  • a culture of colibacteria is implanted in the descending section of colon. In each section not less than 100 ml of liquid culture is administered. More preferably, not less than 20 ml will be administered.
  • the implanted bacteria may be in any phase of growth and the titer will not be less than 10" units/ml. More preferably the bacteria will be in the log phase of growth and the titer will not be less than 10 8 units/ml.
  • liquid lactobacteria is implanted in the vagina.
  • the implanted bacteria may be in any phase of growth and the titer will not be less than 10" units/ml. More preferably the bacteria will be in the log phase of growth and the titer will not be less than 10 8 units/ml. Healthy microflora is also restored in the oral cavity and nasopharynx.
  • liquid lactobacteria culture will be applied.
  • the applied bacteria may be in any phase of growth and the titer will not be less than 10 4 units/ml. More preferably the bacteria will be in the log phase of growth and the titer will not be less than 10 8 units/ml. From 1 to 10 ml will be applied through the oral cavity and from 0.1 to 4 ml through the nose. More preferably, from 3 to 5 ml will be applied through the oral cavity and from 1 to 2 ml through the nose.
  • Electrol ⁇ zing aqueous salt solution also produces solution with a positive redox potential.
  • the aqueous solution with a positive redox potential of +900 to + 1200 mV and pH 1.0 to 2.0 (anolite), has antiseptic, anti- inflammatory and antiproliferative properties.
  • any bacterial strains known in the art may be used.
  • the following strains are preferable: Bifidobacterium bifidum 1 or 791;- Bifidobacterium longum 397; Bifidobacterium adol ⁇ scentis MC-42; and Lactobacillus acidiophilus 317/402.
  • the Bifidobacteria and Lactobacteria are the main components of the microflora of the intestine and urogenital tract of humans. These bacteria are antagonistic to many agents that cause intestinal and urogenital infection, stimulate self-protective mechanisms and increase resistance to many diseases.
  • strain of Lactobacillus acidophilus that may be used in the present invention is Strain
  • Oral, vaginal and rectal administration of bacteria combined with the use of pharmacologically active solutions improves the ability to destroy pathogenic microflora in the intestine and urogenital tract and restore a healthy microflora.
  • the implanted bacteria compete with the pathogenic microflora for binding sites on the epithelial cells of the intestine and urogenital tract, thus displacing the pathogenic microflora and allowing for the development of a healthy microflora.
  • Example 2 To prepare an electroactivated aqueous solution of an admixture of salts, 10 liters of a 1.0% solution of
  • NaCI, KCI, CaCI 2 and MgCI 2 in a ratio of 80:2:2:11 was poured into an Espero membranous electrolyzer. After 30 to
  • the inoculating dose was 3 to 5% by mass, with a titer of 7 x 10 7 units/ml.
  • This culture was grown at 37° C for 18 to 24 hours, until it formed a dense biomass of bacteria that were in the log phase of growth.
  • the acidity of the resulting culture was approximately 100T and the titer of cells was 7 to 9 x 10 9 units/ml.
  • a nutrient medium was prepared, based on skim milk, that contained the components of yeast autolysate, maize extract and ascorbic acid.
  • An inoculating dose of Bifidobacterium adolesce ⁇ tis strain MC-42 was added to the medium in an amount of 5% by volume, with a titer of 10 8 units/ml.
  • the culture was grown at 38" C for 12 hours, producing a dense, even culture in the log phase of growth with a titer of 1 to 3 x10 10 units/ml and an acidity of 100°T. At this point the culture was cooled to 25° C and oxidized to 50 to 80T.
  • Example 5 A sterile nutritive medium was made based on milk and containing sodium citrate in an amount of 0.1 to 0.3 x 10 2 % by mass. The sour of a culture of Lactobacillus acidophilus strain 317/402 was added in an amount of 2 to 5% by mass. The culture was grown at 38° C for 4 to 6 hours, until the bacteria were in the log phase of growth. The resulting culture was maintained in the refrigerator at 5 to 8° C for at least 2 hours. The titer of the bacteria in the liquid product was 2 to 4 x 10 9 units/ml.
  • Example 6 A sterile nutritive medium was made based on milk and containing sodium citrate in an amount of 0.1 to 0.3 x 10 2 % by mass. The sour of a culture of Lactobacillus acidophilus strain 317/402 was added in an amount of 2 to 5% by mass. The culture was grown at 38° C for 4 to 6 hours, until the bacteria were in the log phase of growth. The resulting culture was maintained
  • An inoculating dose of Escherichia coli was introduced onto blood agar with polymyxin and grown to a culture with a titer of not less than 10 8 units/ml.
  • the culture was separated from the nutrient medium after the bacteria had entered the log phase of growth.
  • the first step in the medical treatment of a patient is the diagnosis of the disease and an investigation of the status of the microflora in the intestine, urogenital tract and oral cavity.
  • a special treatment regimen will be developed for each patient, depending on this diagnosis and investigation.
  • the electroactivated aqueous salt solution with negative redox potential can be administered to treat a patient with a weakened immune system and without obvious signs of irritable colon.
  • the weakened immune system may be caused by, for example, catarrhal diseases, herpes etc...
  • the aqueous salt solution with negative redox potential may be administered in one or two intravenous injections per day, totaling no more than 200 ml. This treatment is preferably continued for 7 to 10 days. In another example, 300 ml of this solution may be administered orally before meals for 15 to 20 days.
  • the electroactivated aqueous salt solution with positive redox potential may be administered as an aerosol with particle size of no more than 3.5 microns.
  • From 1 to 3 ml of the aerosol is preferably administered by way of inhalation into the respiratory tract either orally or through the nose twice a day, in the morning and the evening.
  • Example 8 The method of the present invention can also be used to treat patients suffering from generalized viral infections, such as AIDS or hepatitis, who also show symptoms of secondary immunodeficiencies and some disruption of the healthy microflora.
  • the electroactivated aqueous salt solution with negative redox potential, prepared as in Examples 1 or 2 is first administered by intravenous injections. Preferably no more than 200 ml per day Fs administered for the first 7 to 10 days and the treatment should not be continued for more than 15 to 20 days, depending on the health of the patient.
  • the intestine of the patient is preferably cleaned with enemas comprising electroactivated aqueous salt solution with negative redox potential, prepared as in Examples 1 or 2.
  • enemas comprising electroactivated aqueous salt solution with negative redox potential, prepared as in Examples 1 or 2.
  • 0.5 to 1.5 liters of this solution is administered once per day, in any manner known in the art.
  • the patient will rinse the oral cavity and nasopharynx twice a day with 100 to 200 ml of the electroactivated aqueous salt solution with positive redox potential, produced as in Examples 1 and 2.
  • Female patients will also carry out vaginal washes twice a day with 200 ml of the electroactivated aqueous salt solution with this solution.
  • a culture of Lactobacteria as prepared in Example 5 will be placed in the ascending section of the intestine through a biopsy canal.
  • a culture of Bifidobacteria prepared as in Example 3 or 4 will be placed in the transverse section of the intestine.
  • a culture of E. coli prepared as in Example 6 will be placed in the descending section of the large intestine. In each placement, not less than 20 ml of culture will be used.
  • liquid Lactobacteria cultures will be applied to this area. Approximately 3 to 5 ml of culture will be applied orally and 1 to 2 ml through the nose. In addition, for female patients, 5 to 10 ml of liquid Lactobacteria will be applied to the vagina after the completion of the treatment with the electroactivated aqueous solution.
  • Example 9
  • the effect of the treatment was studied on patients with chronic fatigue syndrome.
  • the study consisted of 120 patients, 70% of whom were active women between the ages of 28 and 45 years old.
  • the diagnosis of chronic fatigue syndrome was made based on a complex of a minimum of 8 symptoms that are typical for this disease. These included constant fatigue, insomnia, pain in the muscles and joints, headaches of unknown origin, poor appetite, flaccidit ⁇ , low grade fever, dyspepsia, and diarrhea or constipation. All patients were subjected to the same tests: blood count, urinalysis, immunological blood analysis and expanded bacteriological analysis of the feces.
  • the fecal analysis revealed destruction of the healthy intestinal microflora in all patients. This was diagnosed as irritable colon syndrome of the III or IV degree, characterized by a sharp decrease in the amount of bacillus in the colon and the almost complete absence of Bifidoflora.
  • Example 10 Treatment was carried out as described in Example 8. Within 2 weeks of beginning the treatment, the symptoms of chronic fatigue syndrome disappeared and the levels of hemoglobin, serum antibodies, and other immunological measures were normalized. Example 10
  • Patient A's urogenital tract problem was treated by conventional antibiotic therapy.
  • the psoriasis was treated with desensitizing drugs (calcium chlorate or calcium gluconate), sedative drugs (tincture araliae of valeriana or herb of leonurus), antihistamine drugs (dimedrolum, suprstinum, diazolinum), vitamins and other pharmacological preparations.
  • desensitizing drugs calcium chlorate or calcium gluconate
  • sedative drugs tincture araliae of valeriana or herb of leonurus
  • antihistamine drugs dimedrolum, suprstinum, diazolinum
  • vitamins and other pharmacological preparations were treated conventionally with antiinflammatories, hormonal drugs, keratolytic creams and unguents.
  • Patient P was treated by the method of the present invention.
  • the electroactivated aqueous salt solution with negative redox potential prepared as in Example 1 or 2 was given orally before a meal in an amount of nor more than 300 ml per day for 15 days.
  • the intestine was cleansed once per day with an enema of 0.5 to 1.5 liters of the electroactivated aqueous salt solution with negative redox potential, prepared as in Example 1 or 2.
  • the oral cavity and nasopharynx were rinsed with 100 to 200 ml of electroactivated aqueous salt solution with a positive redox potential prepared as in Example 1 or 2. This was done twice a day.
  • the vagina was washed twice a day with 200 ml of the electroactivated aqueous salt solution with positive redox potential prepared as in Example 1 or 2.
  • intestinal microflora was implanted with the assistance of a colonoscop ⁇ .
  • a culture of Lactobacteria as prepared in Example 5 was placed in the ascending section of the intestine through a biopsy canal.
  • a culture of Bifidobacteria prepared as in Example 3 or 4 was placed in the transverse section of the intestine.
  • a culture of E. coii prepared as in Example 6 was placed in the descending section of the large intestine. In each case, not less than 20 ml of culture was placed. The bacteria in the cultures were in the log phase of growth and at a titer of not less than 10 8 units/ml.
  • liquid Lactobacteria cultures was applied to these areas. Approximately 3 to 5 ml of culture were applied orally and 1 to 2 ml through the nose. In addition, 5 to 10 ml of liquid Lactobacteria were applied to the vaginal cavity.
  • Patient C was diagnosed with AIDS.
  • Laboratory tests revealed the following: creatinine 154; common bilirubin 36 mmol/l; urea 7.6; pH 7.55; pC0 2 27.8; p0 2 89.9; VE +2.7; Hb 90 g/l; HT 33; EKA 26.5 g/l.
  • Immunological tests revealed the following: absolute lymphocytes 480 units; T helpers : T-suppressors 2.0; ATF in lymphocytes of 3.3 units/I (deficit of immunocompetent cells).
  • a microbiological analysis of the feces revealed stage IV dysbacteriosis of the intestine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention a trait à une méthode de traitement d'états pathologiques d'immunodéficience chez l'homme consistant à administrer des solutés salins aqueux électroactivés et à reconstituer ensuite une microflore saine.
EP00961512A 1999-09-01 2000-09-01 Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme Withdrawn EP1189636A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU99118610A RU2149633C1 (ru) 1999-09-01 1999-09-01 Способ лечения иммунодефицитных состояний организма
RU99118610 1999-09-01
PCT/US2000/024194 WO2001015710A2 (fr) 1999-09-01 2000-09-01 Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme

Publications (1)

Publication Number Publication Date
EP1189636A2 true EP1189636A2 (fr) 2002-03-27

Family

ID=20224393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00961512A Withdrawn EP1189636A2 (fr) 1999-09-01 2000-09-01 Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme

Country Status (4)

Country Link
EP (1) EP1189636A2 (fr)
AU (1) AU7345400A (fr)
RU (1) RU2149633C1 (fr)
WO (1) WO2001015710A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US20030180379A1 (en) 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
RU2178300C1 (ru) * 2000-08-17 2002-01-20 Омская государственная медицинская академия Способ лечения больных полипозом толстого кишечника
US7090839B2 (en) 2000-09-01 2006-08-15 Hidden Valley, N.V. Method of treatment of human immunodeficiency diseases
CA2445734A1 (fr) 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. Procede pour induire une apoptose et pour inhiber des metalloproteinases matricielles par utilisation de metaux antimicrobiens
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
RU2209072C2 (ru) * 2001-09-25 2003-07-27 Орловский Евгений Владимирович Антивирусная композиция для лечения вич-инфицированных больных с высокой вирусной нагрузкой
RU2216334C1 (ru) * 2002-02-20 2003-11-20 Роговин Всеволод Викторович Солевой раствор роговина в.в.
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
JP2005120084A (ja) * 2003-09-25 2005-05-12 Hoshizaki Electric Co Ltd 免疫賦活剤、その生成方法および生成装置
RU2290162C2 (ru) * 2004-06-22 2006-12-27 Ашот Папикович Хачатрян Способ комплексного оздоровления пациента и устройство для его реализации
DE102004049338A1 (de) * 2004-07-24 2006-02-16 Behrens, Stephan Verwendung eines Inhalators und dem mit einem Inhalator hergestellen salzhaltigen Aerosol
RU2271209C1 (ru) * 2004-08-12 2006-03-10 Сергей Борисович Авакимян Способ лечения злокачественных опухолей
ATE361101T1 (de) * 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
EP1810683A4 (fr) * 2004-09-27 2008-12-10 Hoshizaki Electric Co Ltd Immunopotentiateur et ses procede et appareil de fabrication
RU2363480C2 (ru) * 2006-11-24 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию" Антидепрессивное средство
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
RU2408377C2 (ru) * 2008-03-20 2011-01-10 Ашот Папикович Хачатрян Способ поддержания жизнедеятельности организма больного, отягощенного онкологическим процессом
JP4524715B2 (ja) * 2008-07-14 2010-08-18 広島化成株式会社 ミネラル含有加水素水およびその製造方法
RU2538086C2 (ru) * 2013-01-29 2015-01-10 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Способ лечения сахарного диабета, осложненного сопутствующими заболеваниями
EP3010853B1 (fr) 2013-06-17 2023-02-22 Nanocomp Technologies, Inc. Agents exfoliants-dispersants pour nanotubes, faisceaux et fibres
EP3253709A4 (fr) 2015-02-03 2018-10-31 Nanocomp Technologies, Inc. Structures à nanotubes de carbone et procédés de production de ceux-ci

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763479A (en) * 1991-02-04 1998-06-09 Ks Biomedix Ltd. Naphthoquinone derivatives for the treatment of chronic inflammation
RU2092167C1 (ru) * 1995-02-22 1997-10-10 Хачатрян Ашот Папикович Способ лечения дисбактериоза кишечника
RU2089194C1 (ru) * 1995-12-14 1997-09-10 Гинтер Елена Константиновна Способ лечения хронической генерализованной вирусной инфекции
RU2077886C1 (ru) * 1996-06-25 1997-04-27 Раиса Николаевна Сумерина Способ лечения инкурабельных больных
RU2122397C1 (ru) * 1997-12-18 1998-11-27 Ашот Папикович Хачатрян Способ получения косметического средства для ухода за кожей

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0115710A2 *

Also Published As

Publication number Publication date
AU7345400A (en) 2001-03-26
WO2001015710A2 (fr) 2001-03-08
WO2001015710A3 (fr) 2002-01-17
RU2149633C1 (ru) 2000-05-27

Similar Documents

Publication Publication Date Title
WO2001015710A2 (fr) Methode de traitement d'etats pathologiques d'immunodeficience chez l'homme
ES2205013T3 (es) Uso de acido hialuronico para el tratamiento de la cistitis intersticial.
Heyworth et al. Polyneuritis associated with cytomegalovirus infections: a report from various centres
Thomson et al. Pseudomembranous colitis after treatment with metronidazole
Blacklock et al. Intramedullary cervical spinal cord abscess: case report
Lacaille et al. Persistent Mycobacterium marinum infection in a child with probable visceral involvement
Gagnon et al. Carpal tunnel syndrome and amyloidosis associated with continuous ambulatory peritoneal dialysis
Vose et al. Recurrent Streptococcus mutans endocarditis
Leung et al. Intraperitoneal hydrocortisone in eosinophilic peritonitis associated with continuous ambulatory peritoneal dialysis
US7090839B2 (en) Method of treatment of human immunodeficiency diseases
TALBOTT The diversity of gouty arthritis and its complications
OILL et al. Adult Haemophilus Injluenzae Type B Vertebral Osteomyelitis: A Case Report and Review of the Literature
Drury et al. Mefenamic acid nephropathy: further evidence
EP0100366A1 (fr) Agent de traitement d'allergies de maladies du complexe immunitaire et de tumeurs
Howells Bilateral recurrent Bell's palsy
McKeghnie et al. Exchange Transfusion in Hepatic Coma.
RU2855922C1 (ru) Способ лечения больных туберкулезом на поздней стадии ВИЧ-инфекции с помощью каскадной плазмофильтрации
Hebb et al. The treatment of lymphopathia venereum with sodium sulfanilyl sulfanilate and sodium sulfanilate
CN105343132A (zh) 治疗结肠炎的组合物、药物及其制备方法
JP2000086524A (ja) 生きた腸内細菌を含有する抗アレルギー剤
Hansson et al. Diamine oxidase (histaminase) and heparin inhibition of gastric secretion in man
RU2146145C1 (ru) Способ комплексной терапии больных хроническим аднекситом, рубцово-спаячным вариантом, неспецифической этиологии
Szczepańska et al. Rasburicase in the treatment of acute kidney injury in a boy with non-malignancy hyperuricemia
Mead et al. Periarticular calcification in paraplegics: attempted treatment with disodium edetate
Ruskin A newer concept of arthritis and the treatment of arthritic pain and deformity by sympathetic block at the sphenopalatien (nasal) ganglion and the use of the iron salt of the adenylic nucleotide: “The dynamics of muscle tonus” PART IV

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 41/00 A

Ipc: 7A 61P 31/18 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030401